DK2229409T3 - Fremgangsmåde til at forøge den terapeutiske effektivitet af immunoglobulin-G-klasse-3-(IgG3)-antistoffer - Google Patents

Fremgangsmåde til at forøge den terapeutiske effektivitet af immunoglobulin-G-klasse-3-(IgG3)-antistoffer

Info

Publication number
DK2229409T3
DK2229409T3 DK08707123.9T DK08707123T DK2229409T3 DK 2229409 T3 DK2229409 T3 DK 2229409T3 DK 08707123 T DK08707123 T DK 08707123T DK 2229409 T3 DK2229409 T3 DK 2229409T3
Authority
DK
Denmark
Prior art keywords
igg3
immunoglobulin
antibodies
class
increasing
Prior art date
Application number
DK08707123.9T
Other languages
English (en)
Inventor
Gestur Vidarsson
Der Schoot Catherine Elisabeth Van
Original Assignee
Sanquin Bloedvoorziening
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanquin Bloedvoorziening filed Critical Sanquin Bloedvoorziening
Application granted granted Critical
Publication of DK2229409T3 publication Critical patent/DK2229409T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK08707123.9T 2008-01-18 2008-01-18 Fremgangsmåde til at forøge den terapeutiske effektivitet af immunoglobulin-G-klasse-3-(IgG3)-antistoffer DK2229409T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2008/000373 WO2009089846A1 (en) 2008-01-18 2008-01-18 Methods for increasing the therapeutic efficacy of immunoglobulin g class 3 (igg3) antibodies

Publications (1)

Publication Number Publication Date
DK2229409T3 true DK2229409T3 (da) 2013-01-14

Family

ID=39654868

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08707123.9T DK2229409T3 (da) 2008-01-18 2008-01-18 Fremgangsmåde til at forøge den terapeutiske effektivitet af immunoglobulin-G-klasse-3-(IgG3)-antistoffer

Country Status (7)

Country Link
US (1) US8426141B2 (da)
EP (1) EP2229409B1 (da)
JP (1) JP5406213B2 (da)
AU (1) AU2008347438B2 (da)
CA (1) CA2710439C (da)
DK (1) DK2229409T3 (da)
WO (1) WO2009089846A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007114319A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
LT2708559T (lt) 2008-04-11 2018-06-11 Chugai Seiyaku Kabushiki Kaisha Antigeną surišanti molekulė, galinti pakartotinai prisijungti prie dviejų ar daugiau antigeno molekulių
WO2012071216A2 (en) 2010-11-22 2012-05-31 Duke University Antibodies for tumor gangliosides
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
MX358220B (es) 2011-11-30 2018-08-10 Chugai Pharmaceutical Co Ltd Portador que contiene fármaco en la célula para formar el inmunocomplejo.
AU2013306700B2 (en) 2012-08-24 2019-05-02 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIb-specific Fc region variant
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
WO2022212191A1 (en) * 2021-04-01 2022-10-06 Modernatx, Inc. Mucosal expression of antibody structures and isotypes by mrna

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US20060134105A1 (en) * 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
US8716451B2 (en) * 2005-01-12 2014-05-06 Kyowa Hakko Kirin Co., Ltd Stabilized human IgG2 and IgG3 antibodies
WO2006075666A1 (ja) * 2005-01-12 2006-07-20 Kyoto University 立体パズル、広告表示物、立体ディスプレイ、およびその作成キット

Also Published As

Publication number Publication date
WO2009089846A1 (en) 2009-07-23
EP2229409A1 (en) 2010-09-22
AU2008347438A1 (en) 2009-07-23
US8426141B2 (en) 2013-04-23
US20110003336A1 (en) 2011-01-06
JP5406213B2 (ja) 2014-02-05
EP2229409B1 (en) 2012-09-26
AU2008347438B2 (en) 2013-08-29
CA2710439A1 (en) 2009-07-23
CA2710439C (en) 2016-04-12
JP2011509951A (ja) 2011-03-31

Similar Documents

Publication Publication Date Title
DK2229409T3 (da) Fremgangsmåde til at forøge den terapeutiske effektivitet af immunoglobulin-G-klasse-3-(IgG3)-antistoffer
DK2152290T3 (da) Fremgangsmåder til indgivelse af anti-il-5-antistoffer
DK3056568T3 (da) Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
DK2034830T3 (da) Anti-vla-1-antistof til behandling af slagtilfælde
DK2643018T3 (da) Anti-il-6-antistoffer til behandling af oral mucositis
DK3401334T5 (da) Monoklonale antistoffer mod claudin-18 til cancerbehandling
DK2076540T3 (da) Hidtil ukendte anti-cd38-antistoffer til behandling af cancer
DK2068874T3 (da) Fremgangsmåder til behandling af multiple myelom med anvendelse af kombinationsterapier baseret på anti-cs1 antistoffer
DK2066695T3 (da) Anti-myostatin-antistoffer
DK2046767T3 (da) Fremgangsmåde til fremstilling af diaminophenothiaziniumforbindelser
DK2001892T3 (da) Imidazolthiazolforbindelser til behandling af proliferative sygdomme
DK2131860T3 (da) Anti-sclerostin-antistoffer
DK1874781T3 (da) Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
ZA200905990B (en) Recombinant antibodies for treatment of respriratory syncytial virus infections
DK2086944T3 (da) Fremgangsmåde til fremstilling af difluormethylpyrazolylcarboxylater
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
BRPI0907532A2 (pt) Anticorpos anti-c5ar humanizados
DK3312197T3 (da) Monoklonale antistoffer mod claudin-18 til behandling af cancer
DK2959894T3 (da) S1p-receptormodulatorer til behandling af multipel sklerose
DK2048941T3 (da) Fremgangsmåde til opdræt af rovmider
DK2242771T3 (da) Bindingsmolekyler til den humane ox40-receptor
DK2292663T3 (da) Antagonistiske human-let-specifikke, humane monoklonale antistoffer
BRPI0819210A2 (pt) Anticorpos de proteína g anti-rsv
DK2307042T3 (da) Modulering af trpv: vps10p-domænereceptorsystem til behandlingen af smerte
DK2672979T3 (da) Anti-cd4-antistoffer til forebyggelse af især graft-versus-host-sygdom (gvhd)